Inozyme Pharma Inc., a Delaware-based company, has announced new compensation terms in light of its recent merger agreement with BioMarin Pharmaceutical, Inc. As part of the agreement, Inozyme's Board of Directors has approved transaction bonuses for key executives. Chief Financial Officer and Head of Business Development, Mr. Sanjay Subramanian, is set to receive a cash bonus of $350,000, while Dr. Matthew Winton, the Senior Vice President and Chief Operating Officer, will be awarded $320,000. These bonuses will be issued following the completion of the merger, contingent upon their continued employment until the closing date, with payments to be made within 30 days thereafter.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。